Radiation therapy facility risk analysis in Brazil with SEVRRA software.

J Radiol Prot

Comissão Nacional de Energia Nuclear-CNEN, R. General Severiano, 90, 22290-151, Rio de Janeiro, RJ, Brazil. Pós-Graduação em Ciências e Técnicas Nucleares-Escola de Engenharia-DEN/UFMG, Av. Presidente Antônio Carlos, 6.627, 31270-901, Belo Horizonte, MG, Brazil.

Published: September 2018

Risk assessment deals with processes, accident-initiating events, barriers and risk ratings to unveil the fragility and weakness of some processes; within this study, specifically related to radiation therapy facilities. Barriers are technical or organizational safety measures put in place to avoid, prevent, detect, control, reduce or mitigate the consequences of an accident once an initiating event has occurred. In this work, radiological risk analysis was performed for a set of 20 Brazilian radiotherapy facilities making use of the freeware sevrra risk-management software. The objective of this study was to define parameters that could be useful in creating an overall risk profile. This profile would be helpful for establishing priorities for decision making and support a risk-informed regulatory process. The most relevant missing barriers in facilities were identified according to three parameters: the 'importance index', 'impacted facilities index' and the 'barrier-effectiveness index'. Barriers such as 'in vivo dosimetry in the first treatment session', 'weekly in vivo dosimetry to detect errors in the dose delivering process', 'annual external audit for the control of reference dose rate' and 'independent verification of calibration by various medical physicists with a different dosimetry equipment' were found to be the most effective in reducing the risk level of the facilities. The present investigation reinforces the need to strengthen the mechanisms that guarantee the effectiveness of such barriers in radiation therapy procedures.

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6498/aad919DOI Listing

Publication Analysis

Top Keywords

radiation therapy
12
risk analysis
8
vivo dosimetry
8
risk
6
barriers
5
facilities
5
therapy facility
4
facility risk
4
analysis brazil
4
brazil sevrra
4

Similar Publications

Today, cancer has become one of the leading global tragedies. It occurs when a small number of cells in the body mutate, causing some of them to evade the body's immune system and proliferate uncontrollably. Even more irritating is the fact that patients with cancers frequently relapse after conventional chemotherapy and radiotherapy, leading to additional suffering.

View Article and Find Full Text PDF

Background: There is no consensus regarding the optimal regimen for metastatic nasopharyngeal carcinoma (dmNPC). Locoregional intensity modulated radiotherapy (LRRT) following palliative chemotherapy (PCT) has been shown to prolong the overall survival (OS) and improve the progression-free survival (PFS) of patients with dmNPC, compared with PCT alone. However, patients with a high tumor burden do not benefit from additional LRRT, which inevitably results in toxicity.

View Article and Find Full Text PDF

Background: Hypothyroidism is a common sequela after radiotherapy for nasopharyngeal carcinoma (NPC). Magnetic resonance imaging (MRI) has gained prominence in thyroid imaging, leveraging its non-ionizing radiation, high spatial resolution, multiparameter and multidirectional imaging. Few previous studies have investigated the evaluation of radiation-induced thyroid injury by MRI.

View Article and Find Full Text PDF

Older patients represent a unique and vulnerable subgroup, requiring careful consideration when determining treatment options. Treatment-related leukoencephalopathy is commonly observed in older patients months to years after receiving radiotherapy and/or methotrexate for primary central nervous system lymphoma (PCNSL). Tirabrutinib is an orally available, highly selective, and potent second-generation Bruton's tyrosine kinase inhibitor (BTKi) approved for treating recurrent/refractory PCNSL in Japan.

View Article and Find Full Text PDF

Microcystic adnexal carcinoma (MAC) is a rare, slow-growing, locally aggressive malignant, and recurring appendageal tumor. Prolonged UV exposure, immunosuppression, and radiotherapy are a few frequently associated risk factors. MAC classically presents as an asymptomatic skin coloured plaque on the face.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!